The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial.

Rafati, Mohammadreza; Mahmoudian, Reza; Golpour, Masoud; Kazeminejad, Armaghan; Saeedi, Majid; Nekoukar, Zahra

Rafati, Mohammadreza; Mahmoudian, Reza; Golpour, Masoud; Kazeminejad, Armaghan; Saeedi, Majid; Nekoukar, Zahra.

Afiliación

Rafati M; Department of Clinical Pharmacy, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Mahmoudian R; Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Golpour M; Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Kazeminejad A; Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Saeedi M; Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Nekoukar Z; Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

Dermatol Ther ; 35(6): e15450, 2022 06.

Article en En | MEDLINE | ID: mdl-35289043

Asunto(s)

Alopecia Areata; Alopecia/tratamiento farmacológico; Alopecia Areata/tratamiento farmacológico; Método Doble Ciego; Humanos; Latanoprost/efectos adversos; Cuero Cabelludo; Resultado del Tratamiento

Palabras clave

alopecia areata; hair loss; latanoprost; scalp; treatment efficacy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alopecia Areata Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Dermatol Ther Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google